Y Intercept Hong Kong Ltd Takes Position in Aurinia Pharmaceuticals Inc $AUPH

Y Intercept Hong Kong Ltd bought a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 71,458 shares of the biotechnology company’s stock, valued at approximately $1,059,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BOK Financial Private Wealth Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $32,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Aurinia Pharmaceuticals in the third quarter worth $48,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth $82,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Aurinia Pharmaceuticals by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 1,318 shares during the period. Finally, Cornerstone Investment Partners LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $178,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Get Aurinia Pharmaceuticals alerts:

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 343,620 shares of the stock in a transaction dated Monday, June 1st. The stock was bought at an average cost of $15.28 per share, for a total transaction of $5,250,513.60. Following the completion of the purchase, the chief executive officer directly owned 12,838,101 shares of the company’s stock, valued at approximately $196,166,183.28. The trade was a 2.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have bought 814,606 shares of company stock valued at $12,455,129. Corporate insiders own 12.20% of the company’s stock.

Aurinia Pharmaceuticals Stock Down 4.9%

NASDAQ:AUPH traded down $0.81 during trading hours on Friday, hitting $15.78. The stock had a trading volume of 1,201,883 shares, compared to its average volume of 1,988,220. The company has a market cap of $2.03 billion, a PE ratio of 7.27 and a beta of 1.41. The business has a 50 day simple moving average of $16.00 and a two-hundred day simple moving average of $15.38. Aurinia Pharmaceuticals Inc has a 1-year low of $8.55 and a 1-year high of $19.25. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The business had revenue of $77.71 million for the quarter, compared to analysts’ expectations of $76.98 million. Analysts predict that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current year.

Analyst Upgrades and Downgrades

AUPH has been the subject of a number of research reports. Zacks Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Read Our Latest Analysis on Aurinia Pharmaceuticals

About Aurinia Pharmaceuticals

(Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

Read More

• Five stocks we like better than Aurinia Pharmaceuticals
• 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
• Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
• Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
• This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP).

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.